FDA rescinds emergency authorization for COVID-19 antibody treatment bamlanivimab

The Food and Drug Administration (FDA) rescinded its emergency use authorization for the monoclonal antibody bamlanivimab to be used on its own as treatment against COVID-19 due to variants’ resistance to the therapy.The federal agency declared its…